$HOTH
Hoth Therapeutics, Inc. Stock $hoth

$hoth Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071279 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.773M	$864.4K	$884.6K
YoY Change	42.46%	-2.28%	-31.95%
% of Gross Profit
Research & Development	$1.474M	$1.451M	$2.163M
YoY Change	-24.68%	-32.89%	188.34%
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change
% of Gross Profit
Operating Expenses	$3.421M	$2.684M	$3.253M
YoY Change	1.21%	-17.48%	49.92%
Operating Profit		-$2.684M	-$3.253M
YoY Change		-17.48%
Interest Expense	-$468.0K	$40.77K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$410.3K	$40.18K	-$42.85K
YoY Change	-510.39%	-193.77%	-185.7%
Pretax Income	-$3.479M	-$2.644M	-$3.296M
YoY Change	-0.04%	-19.78%	55.47%
Income Tax
% Of Pretax Income
Net Earnings	-$3.479M	-$2.644M	-$3.296M
YoY Change	-0.04%	-19.78%	55.47%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.05	-$3.45
Diluted Earnings Per Share	-$2.68	-$2.05	-$138.0K
COMMON SHARES
Basic Shares Outstanding	1.300M shares	32.21M shares	955.5K shares
Diluted Shares Outstanding		1.288M shares	955.5K shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.638M	$9.266M	$14.48M
YoY Change	-36.36%	-36.0%	167.6%
Cash & Equivalents	$6.429M	$8.935M	$12.45M
Short-Term Investments	$209.3K	$330.9K	$2.032M
Other Short-Term Assets	$88.45K	$191.4K	$250.4K
YoY Change	-5.87%	-23.55%	212.96%
Inventory
Prepaid Expenses	$88.45K	$191.4K
Receivables
Other Receivables
Total Short-Term Assets	$6.726M	$9.507M	$14.78M
YoY Change	-36.39%	-35.66%	169.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$33.00K	$387.4K	$410.0K
YoY Change	-91.95%	-5.51%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$33.00K	$387.4K	$410.0K
YoY Change	-91.95%	-5.51%	-10.87%
TOTAL ASSETS
Total Short-Term Assets	$6.726M	$9.507M	$14.78M
Total Long-Term Assets	$33.00K	$387.4K	$410.0K
Total Assets	$6.759M	$9.895M	$15.19M
YoY Change	-38.47%	-34.85%	155.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$695.0K	$930.9K	$1.301M
YoY Change	92.54%	-28.47%	6406.9%
Accrued Expenses	$667.7K	$52.50K	$305.3K
YoY Change	56.44%	-82.8%	-44.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.388M	$1.008M	$1.607M
YoY Change	59.92%	-37.23%	181.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$250.0K	$275.0K	$235.0K
YoY Change	6.38%	17.02%
Total Long-Term Liabilities	$250.0K	$275.0K	$235.0K
YoY Change	6.38%	17.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.388M	$1.008M	$1.607M
Total Long-Term Liabilities	$250.0K	$275.0K	$235.0K
Total Liabilities	$1.638M	$1.283M	$1.842M
YoY Change	48.51%	-30.31%	223.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$45.10M	-$41.62M
YoY Change	33.72%
Common Stock	$130.00	$129.00
YoY Change	-94.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.122M	$8.611M	$13.35M
YoY Change
Total Liabilities & Shareholders Equity	$6.759M	$9.895M	$15.19M
YoY Change	-38.47%	-34.85%	155.26%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$3.479M	-$2.644M	-$3.296M
YoY Change	-0.04%	-19.78%	55.47%
Depreciation, Depletion And Amortization			$0.00
YoY Change
Cash From Operating Activities	-$2.550M	-$2.389M	-$2.703M
YoY Change	-34.65%	-11.62%	80.19%
INVESTING ACTIVITIES
Capital Expenditures	$7.500K	$9.950K	-$91.60K
YoY Change	-142.93%	-110.86%	205.33%
Acquisitions
YoY Change
Other Investing Activities	$10.00	-$10.00	-$487.5K
YoY Change	-200.0%	-100.0%	-169.65%
Cash From Investing Activities	-$7.490K	$9.950K	-$579.1K
YoY Change	-57.15%	-101.72%	-186.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.99K	0.000	-100.0K
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-2.550M	-2.389M	-2.703M
Cash From Investing Activities	-7.490K	9.950K	-579.1K
Cash From Financing Activities	50.99K	0.000	-100.0K
Net Change In Cash	-2.507M	-2.379M	-3.382M
YoY Change	-36.05%	-29.66%	307.47%
FREE CASH FLOW
Cash From Operating Activities	-$2.550M	-$2.389M	-$2.703M
Capital Expenditures	$7.500K	$9.950K	-$91.60K
Free Cash Flow	-$2.558M	-$2.399M	-$2.611M
YoY Change	-34.16%	-8.14%	77.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10020
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38803
	dei	Entity Registrant Name EntityRegistrantName	Hoth Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1553794
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Rockefeller Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1039
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1288493	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	756-2997
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	HOTH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1300382	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8935081	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8538270	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	330901	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1892837	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	191424	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93972	usd
CY2022Q3	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	50000	usd
CY2021Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	50000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	9507406	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10575079	usd
CY2022Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	387400	usd
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	410000	usd
CY2022Q3	us-gaap	Assets Assets	9894806	usd
CY2021Q4	us-gaap	Assets Assets	10985079	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	930925	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	360964	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52502	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	426823	usd
CY2022Q3	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	25000	usd
CY2021Q4	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	80000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1008427	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	867787	usd
CY2022Q3	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	275000	usd
CY2021Q4	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	235000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1283427	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1102787	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1288493	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	959009	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	959009	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	129	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50182173	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43591773	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41620494	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33727163	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	49571	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17586	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8611379	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9894806	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10985079	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1451280	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2123548	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3370841	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5408166	usd
CY2022Q3	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	16953	usd
CY2021Q3	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	38967	usd
	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	94678	usd
	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	164812	usd
CY2022Q3	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	348754	usd
CY2021Q3	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	358699	usd
	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	1821613	usd
	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	2488775	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	498034	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	519592	usd
	us-gaap	Professional Fees ProfessionalFees	1508330	usd
	us-gaap	Professional Fees ProfessionalFees	2021151	usd
CY2022Q3	hoth	Rent Expenses RentExpenses	17625	usd
CY2021Q3	hoth	Rent Expenses RentExpenses	6297	usd
	hoth	Rent Expenses RentExpenses	47112	usd
	hoth	Rent Expenses RentExpenses	32634	usd
CY2022Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	351767	usd
CY2021Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	206093	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	802080	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	605787	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2684413	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3253196	usd
	us-gaap	Operating Expenses OperatingExpenses	7644654	usd
	us-gaap	Operating Expenses OperatingExpenses	10721325	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2684413	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3253196	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7644654	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10721325	usd
CY2022Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	40774	usd
CY2021Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-13717	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-266908	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-51658	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-22600	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-592	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29135	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	40831	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60628	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	40182	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-42852	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-248677	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-112286	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2644231	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3296048	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7893331	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10833611	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	21485	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19601	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	31985	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	35138	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2622746	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3276447	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7861346	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10798473	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.44
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1288481	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	955538	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1164174	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	871062	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11221771	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12354	usd
CY2022Q3	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	21485	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2644231	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8611379	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	16574613	usd
CY2021Q3	hoth	Net Of Offering Costs NetOfOfferingCosts	1591600	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-100000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23897	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	124000	usd
CY2021Q3	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	19601	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3296048	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13346063	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5985103	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18194646	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	605330	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1014896	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5985103	usd
	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	31985	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7893331	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8611379	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4645593	usd
	hoth	Issuance Of Common Stock Common Stock Warrants And Prefunded Warrants IssuanceOfCommonStockCommonStockWarrantsAndPrefundedWarrants	1591600	usd
	hoth	Issuance Of Common Stock Common Stock Warrants And Prefunded Warrantsnet Of Offering Costs IssuanceOfCommonStockCommonStockWarrantsAndPrefundedWarrantsnetOfOfferingCosts	13407632	usd
	hoth	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	572500	usd
	hoth	Issuance Of Common Stock And Warrantnet Of Offering Costs IssuanceOfCommonStockAndWarrantnetOfOfferingCosts	4427501	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	359513	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1180297	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	124000	usd
	hoth	Stock Issued During Period Value Cumulative Translation Adjustment StockIssuedDuringPeriodValueCumulativeTranslationAdjustment	35138	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10833611	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13346063	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7893331	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10833611	usd
	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	51500	usd
	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	82500	usd
	hoth	Change In Fair Value Of Investments In Joint Ventures ChangeInFairValueOfInvestmentsInJointVentures	22600	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	605330	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1180297	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	16533	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-194179	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-41798	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-132063	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-37843	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-60628	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	105428	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	54740	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	245296	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1280821	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6747791	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8187931	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	66500	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	99500	usd
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-2556126	usd
	hoth	Sale Of Marketable Securities SaleOfMarketableSecurities	1235694	usd
	hoth	Sale Of Marketable Securities SaleOfMarketableSecurities	2507750	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1169194	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-147876	usd
	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO	13407632	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4427501	usd
	hoth	Proceeds From Issuance Common Stock Net Of Offering Cost ProceedsFromIssuanceCommonStockNetOfOfferingCost	5985103	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9695	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	359513	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-43130	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	406506	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9858839	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8538270	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2629670	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8935081	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12445379	usd
	us-gaap	Stock Issued1 StockIssued1	124000	usd
CY2022Q2	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	329412	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	21.25
CY2022Q2	hoth	Additional Purchase Shares AdditionalPurchaseShares	49412	shares
CY2022Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	6000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	507527	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	455815	shares
	hoth	Schedule Of Research And Development Expenses For Licenses Acquired ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,953</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,178</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">82,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Isoprene Pharmaceuticals, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>University of Cincinnati</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,953</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">38,967</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">94,678</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">164,812</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
CY2022Q3	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	16953	usd
CY2021Q3	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	38967	usd
	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	94678	usd
	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	164812	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	12000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	43000	usd
CY2022Q3	hoth	Accrued License Fee AccruedLicenseFee	275000	usd
CY2022Q3	hoth	Maintenance Fees MaintenanceFees	25000	usd
	hoth	Note Receivable NoteReceivable	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4-Note Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the sublicense agreement dated July 30, 2020 by and between the Company and Isoprene Pharmaceuticals, Inc. (“Isoprene”), the Company made an investment of $50,000 in Isoprene in the form of a convertible promissory note (the “Isoprene Note”) on September 10, 2020. The Isoprene Note was due to mature on September 10, 2022 and accrues interest at a rate equal to the lower of: (i) the highest lawful rate permitted under applicable law and (ii) 6% per annum. The Isoprene Note may not be prepaid without the prior written consent of the Company; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that if the Isoprene Note has not been converted in connection with a Qualified Financing (as defined herein) or Change of Control (as defined in the Isoprene Note) by the two year anniversary of the date of the issuance of the Isoprene Note, Isoprene may elect, in its sole discretion, to repay the Isoprene Note and any accrued interest thereon. In the event a Qualified Financing occurs before the Isoprene Note is repaid in full on the maturity date or the conversion of such note pursuant to a Change of Control, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price. “Qualified Financing” means the first sale of Isoprene’s convertible preferred stock in a private financing that results in gross proceeds of at least $5 million. “Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization of Isoprene immediately prior to the conversion of the Isoprene Note. In the event a Change of Control occurs before the Isoprene Note is repaid in full on the maturity date or the conversion of such note pursuant to a Qualified Financing, the Isoprene Note may be converted into such number of shares of Isoprene’s common stock equal to the quotient obtained by dividing (i) the balance of the Isoprene Note by (ii) two times the fair market value of a share of Isoprene common stock as set for in the acquisition agreement pertaining to such Change of Control. As of the maturity date of the Isoprene Note, neither a Qualified Financing nor a Change of Control had occurred. As such, as of September 30, 2022, the Isoprene Note was deemed a receivable of the Company. The Isoprene Note and accrued interest was paid off on October 21, 2022.</p>
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	50000	usd
CY2022Q3	us-gaap	Investment Interest Rate InvestmentInterestRate	0.06	pure
	hoth	Note Receivable Description NoteReceivableDescription	Qualified Financing (as defined herein) or Change of Control (as defined in the Isoprene Note) by the two year anniversary of the date of the issuance of the Isoprene Note, Isoprene may elect, in its sole discretion, to repay the Isoprene Note and any accrued interest thereon. In the event a Qualified Financing occurs before the Isoprene Note is repaid in full on the maturity date or the conversion of such note pursuant to a Change of Control, the Isoprene Note may be converted into such number of convertible preferred stock issued in the Qualified Financing equal to the balance of such note divided by the Capped Conversion Price. “Qualified Financing” means the first sale of Isoprene’s convertible preferred stock in a private financing that results in gross proceeds of at least $5 million.
	hoth	Conversion Price Description ConversionPriceDescription	“Capped Conversion Price” means the lesser of (i) the per share or unit price in the Qualified Financing and (ii) an amount determined by dividing (A) $15 million by (B) the fully diluted capitalization of Isoprene immediately prior to the conversion of the Isoprene Note.
CY2022Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	26572	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	9566	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-132063	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-37843	usd
CY2021Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-41214	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-194179	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-41798	usd
CY2022Q3	us-gaap	Dividend Income Operating DividendIncomeOperating	14202	usd
CY2021Q3	us-gaap	Dividend Income Operating DividendIncomeOperating	17931	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	59334	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	27983	usd
CY2022Q3	hoth	Other Income Nets OtherIncomeNets	40774	usd
CY2021Q3	hoth	Other Income Nets OtherIncomeNets	-13717	usd
	hoth	Other Income Nets OtherIncomeNets	-266908	usd
	hoth	Other Income Nets OtherIncomeNets	-51658	usd
	hoth	Marketable Securities Mutual Funds MarketableSecuritiesMutualFunds	330901	usd
CY2022Q3	hoth	Investment In Joint Venture InvestmentInJointVenture	387400	usd
CY2022Q3	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	50000	usd
CY2021	hoth	Marketable Securities Mutual Funds MarketableSecuritiesMutualFunds	1892837	usd
CY2021Q4	hoth	Investment In Joint Venture InvestmentInJointVenture	410000	usd
CY2021Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	50000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	410000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-22600	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	387400	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	23000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	66878	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	96000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	100	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	64	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	75
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	36	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	75
	hoth	Unvested Restricted Stock Awards Term unvestedRestrictedStockAwardsTerm	P0Y3M3D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	52851	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	84.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	51800	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.75
	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualIssued	P9Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104651	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
	hoth	Rfl Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 rfl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	104651	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	49.8
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
	hoth	Proceeds From Issuance Common Stock Net Of Offering Cost ProceedsFromIssuanceCommonStockNetOfOfferingCost		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
	hoth	Share Based Componsation Intrinsic Value Employee Options Issued ShareBasedComponsationIntrinsicValueEmployeeOptionsIssued		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12354	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40430	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	605330	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1196830	usd
	hoth	Schedule Of Warrant Activity ScheduleOfWarrantActivity	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average<br/> Remaining Contractual<br/> Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 1.5pt">Outstanding as of December 31, 2021</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">402,840</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">49.83</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"> -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2.3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Outstanding as of September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,840</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49.83</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.6</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of September 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">401,312</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49.73</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.8</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
	hoth	Leases Office Spaces LeasesOfficeSpaces	4500	usd
CY2022Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	18000	usd
CY2021Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	6000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	47000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	33000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1164174	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	hoth	Change In Fair Value Of Investments In Joint Ventures ChangeInFairValueOfInvestmentsInJointVentures		usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation		usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities		usd
	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001711786

Files In Submission

Name	View Source	Status
0001213900-22-071279-index-headers.html	Edgar Link	pending
0001213900-22-071279-index.html	Edgar Link	pending
0001213900-22-071279.txt	Edgar Link	pending
0001213900-22-071279-xbrl.zip	Edgar Link	pending
f10q0922ex10-1_hoththerap.htm	Edgar Link	pending
f10q0922ex31-1_hoththerap.htm	Edgar Link	pending
f10q0922ex31-2_hoththerap.htm	Edgar Link	pending
f10q0922ex32-1_hoththerap.htm	Edgar Link	pending
f10q0922ex32-2_hoththerap.htm	Edgar Link	pending
f10q0922_hoththerap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hoth-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
hoth-20220930_def.xml	Edgar Link	unprocessable
hoth-20220930_lab.xml	Edgar Link	unprocessable
f10q0922_hoththerap_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hoth-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
hoth-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOTH
Hoth Therapeutics, Inc. Stock $hoth

2022 Q4 Form 10-Q Financial Statement

#000121390022071279 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH Hoth Therapeutics, Inc. Stock $hoth

2022 Q4 Form 10-Q Financial Statement

#000121390022071279 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH
Hoth Therapeutics, Inc. Stock $hoth